The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

Tickets sold out so quickly for today’s Labour party conference “business day” that it was dubbed the corporate equivalent of ...

Discover the potential of nature-based real assets for institutional investors. Learn how HSBC and Pollination's Climate Asset Management is leading the way.

Tickets sold out so quickly for today’s Labour party conference “business day” that it was dubbed the corporate equivalent of ...

The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...

comments a Future Market Insights analyst. Zydus Healthcare Ltd., Sun Pharmaceutical Industries Ltd., Sanofi SA, GSK Plc, ...

Peripheral blood mononuclear cells (PBMCs) collected from 10 patients with active AS patients were exposed to TP, GSK-J4 or vehicle. T lymphocyte subsets were analyzed using flow cytometry. ELISA was ...

Allison Freedman is opening up about her fight with multiple myeloma during Blood Cancer Awareness Month. She went from being ...